These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 31655410)
21. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. O'Dell MW; Brashear A; Jech R; Lejeune T; Marque P; Bensmail D; Ayyoub Z; Simpson DM; Volteau M; Vilain C; Picaut P; Gracies JM PM R; 2018 Jan; 10(1):1-10. PubMed ID: 28634000 [TBL] [Abstract][Full Text] [Related]
22. A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines. Punga AR; Alimohammadi M; Fagrell D; Nyberg F; Rees D; Wong C Dermatol Surg; 2016 Aug; 42(8):967-76. PubMed ID: 27399956 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. Jost WH; Kohl A; Brinkmann S; Comes G J Neural Transm (Vienna); 2005 Jul; 112(7):905-13. PubMed ID: 15526142 [TBL] [Abstract][Full Text] [Related]
24. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals. Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439 [TBL] [Abstract][Full Text] [Related]
25. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Eleopra R; Tugnoli V; Rossetto O; Montecucco C; De Grandis D Neurosci Lett; 1997 Mar; 224(2):91-4. PubMed ID: 9086464 [TBL] [Abstract][Full Text] [Related]
26. Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B. Ponmariappan S; Jain S; Sijoria R; Tomar A; Kumar O Protein Pept Lett; 2012 Mar; 19(3):288-98. PubMed ID: 21933129 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins. Oh HM; Park JH; Song DH; Chung ME Toxins (Basel); 2015 Dec; 8(1):. PubMed ID: 26712786 [TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. Hyman N; Barnes M; Bhakta B; Cozens A; Bakheit M; Kreczy-Kleedorfer B; Poewe W; Wissel J; Bain P; Glickman S; Sayer A; Richardson A; Dott C J Neurol Neurosurg Psychiatry; 2000 Jun; 68(6):707-12. PubMed ID: 10811692 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study. Kwanchuay P; Petchnumsin T; Yiemsiri P; Pasuk N; Srikanok W; Hathaiareerug C J Med Assoc Thai; 2015 Dec; 98(12):1231-6. PubMed ID: 27004309 [TBL] [Abstract][Full Text] [Related]
30. AbobotulinumtoxinA (Dysport Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641 [TBL] [Abstract][Full Text] [Related]
31. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Eleopra R; Tugnoli V; Rossetto O; De Grandis D; Montecucco C Neurosci Lett; 1998 Nov; 256(3):135-8. PubMed ID: 9855358 [TBL] [Abstract][Full Text] [Related]
32. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Rubin M; Dover J; Maas C; Nestor M Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005 [TBL] [Abstract][Full Text] [Related]
33. Acute neurophysiologic effects of botulinum toxin type A intramuscular injection on extensor digitorum brevis muscle in healthy adults. Boulias C; Ismail F; Phadke CP Toxicon; 2022 May; 211():6-10. PubMed ID: 35283163 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585 [TBL] [Abstract][Full Text] [Related]
35. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients. Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800 [TBL] [Abstract][Full Text] [Related]
36. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview. Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120 [TBL] [Abstract][Full Text] [Related]